How Good was 2015 for the French Universal CAR-T Biotech?

16/03/2016 - 3 minutes

Cellectis (France) has now released its financial results for 2015. What happened and what the prospects for 2016 and long-term?

cellectis_ucart_leukemia_cancer_gmp_allogeneic_universal_2015_financial_resultsIt was a really packed year for Cellectis, the French Champion for universal, off-the-shelf CAR-T treatments. The Biopharma saw significant advances in multiple fronts, from clinical development to financing.

The first therapy initially developed by Cellectis, UCART19, was submitted to UK’s regulation just before Christmas to initiate phase I trials in the UK. This is a substantial milestone, even if not as wildly publicized as the success of the first-in-human use of the candidate – the remission of terminal leukemia in 1-year-old Layla, at Great Ormond Street Hospital (GOSH) in London, was close to miraculous.

UCART19 is now being developed by Servier (an option Servier had after entering in a partnership that saved Cellectis from bankruptcy) and will be licensed in collaboration with Pfizer (a rather unusual deal).

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member